Phasing forward with Seqens
Three custom development and manufacturing organizations – PCAS S.A. in France, Chemie Uetikon in Germany and PCI Synthesis in the United States –…
Read moreDOWNLOAD THE PRESS RELEASE Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical molecules.Their…
Read moreDidier Combis of Seqens CDMO explains why pharmaceutical companies should consider the specifics of the API when dealing with drug lifecycle management…
Read more4 Best Practices For Taking the Right Precautions to Develop Safe and Effective controlled Substances By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO…
Read moreThe Growth of the Generic Drug Marketplace: A Win-Win for Industry and Patients By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO Some…
Read moreProprietary intermediates produced in Europe, U.S. rather than imported Across the world, the pressure to cut drug price costs has never been greater.
Read moreWorking with Contract Development & Manufacturing Organizations (CDMOs) in Asia has become a popular strategy for European and U.S.-based sponsors because of the associated…
Read moreSEQENS has decided to invest €65M to increase its development and production capacities for active ingredients and pharmaceutical intermediates and to accelerate…
Read moreShifting needs in the pharmaceutical market are driving a stronger demand for specialized production units to manufacture highly potent active…
Read moreFounded in 1991, The site of Lahr is part of SEQENS CDMO since mid-2015. The site is specialized in the development and manufacturing…
Read moreDOWNLOAD THE PRESS RELEASE Gérard Guillamot SEQENS Scientific Director Due to the urgency of finding a treatment against CoVid-19,…
Read moreA new warehouse for active ingredients The production of active ingredients on site Lahr has increased steadily over the last years. It was…
Read moreDOWNLOAD THE PRESS RELEASE Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical molecules.Their…
Read moreDidier Combis of Seqens CDMO explains why pharmaceutical companies should consider the specifics of the API when dealing with drug lifecycle management…
Read moreBy, Didier Combis, Commercial Director, Seqens CDMO; Christine Adam, Business Development Manager, Unither Pharmaceuticals and Jean Francois Cordoliani, Site Director, Unither Développement Bordeaux…
Read moreBy Don LaFerle, Senior Vice President, Custom Synthesis, Seqens CDMO The ICH Q7 defines RSMs (Regulatory Starting Materials) as the point at…
Read moreThe Villeneuve-la-Garenne plant continues its transformation through the Potent project, which will enable the group to access the production of active pharmaceutical ingredients…
Read more